Advertisement

Document › Details
Veraxa Biotech GmbH. (3/22/22). "Press Release: Torsten Buergermeister Joins Veraxa Biotech GmbH as Chief Financial Officer". Heidelberg.
The new CFO brings extensive experience in finance and business development at life science, pharma and technology companies.
Torsten Buergermeister has been appointed Chief Financial Officer (CFO) of VERAXA Biotech, based in Heidelberg, Germany. Buergermeister joins VERAXA from Molecular Health, an international Precision Medicine company where he had global responsibilities as Senior Vice President of Finance.
“Torsten brings excellent financial managing skills with a very good knowledge of biotech and related capital markets,” said Dr. Christoph Antz, CEO of VERAXA. “We are excited to have him join our management team.”
About VERAXA Biotech
VERAXA’S mission is to tackle two of the biggest challenges in antibody drug development: Antibody discovery and ADC development. The company’s droplet-based microfluidic screening technology and its innovative antibody and protein conjugation technology allows for a rapid generation of antibodies against most complex target molecules and for a target product profile sharpening of existing monoclonal antibody candidates in oncology or precision medicine. VERAXA Biotech GmbH is a fusion of Velabs Therapeutics GmbH and Araxa Biosciences GmbH, both spin-off companies from European Molecular Biology Laboratory (EMBL), Europe’s most renowned institute for life science research and instrument development. VERAXA is a preferred license and cooperation partner of global biotech and pharma industries.
Record changed: 2022-04-05 |
Advertisement
![Picture [iito] No Tracking 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-no-tracking.jpg)
More documents for Veraxa Biotech (Group)
- [1] Indivumed GmbH. (8/10/21). "Press Release: Veraxa Biotech and Indivumed Cooperate on the Development of Precision Oncology Antibody Drugs". Heidelberg & Hamburg....
- [2] Veraxa Biotech GmbH. (6/14/21). "Press Release: Veraxa Biotech and Quadira Biosciences Enter Partnership on ADC Development". Heidelberg....
- [3] Velabs Therapeutics GmbH. (1/7/20). "Press Release: Velabs Therapeutics Receives Exclusive Licence from Alytas Therapeutics for the Development of Therapeutic Antibodies as Senolytics". Heidelberg & Jena....
- [4] Velabs Therapeutics GmbH. (6/27/19). "Press Release: Velabs Therapeutics Announces €3 Million Series B Financing to Advance its Functional Antibody Screening Programme". Heidelberg....
- [5] Velabs Therapeutics GmbH. (4/24/19). "Press Release: Velabs Therapeutics to Cooperate with Chiome Bioscience in the Field of GPCR-Specific Functional Antibody Screening". Heidelberg....
- [6] BioMed X GmbH. (1/7/19). "Press Release: Velabs Therapeutics to Cooperate with BioMed X in the Field of Immunology". Heidelberg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top